(19)
(11) EP 2 344 672 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
24.12.2014 Bulletin 2014/52

(45) Mention of the grant of the patent:
12.11.2014 Bulletin 2014/46

(21) Application number: 09816583.0

(22) Date of filing: 25.09.2009
(51) International Patent Classification (IPC): 
C12Q 1/68(2006.01)
C12N 15/11(2006.01)
(86) International application number:
PCT/US2009/005318
(87) International publication number:
WO 2010/036353 (01.04.2010 Gazette 2010/13)

(54)

GENETIC MARKERS FOR OPTIMIZING TREATMENT FOR SCHIZOPHRENIA

GENETISCHE MARKER ZUR OPTIMIERUNG EINER SCHIZOPHRENIEBEHANDLUNG

MARQUEURS GÉNÉTIQUES POUR OPTIMISER LE TRAITEMENT DE LA SCHIZOPHRÉNIE


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 25.09.2008 US 100176 P

(43) Date of publication of application:
20.07.2011 Bulletin 2011/29

(60) Divisional application:
14192641.0

(73) Proprietor: SureGene LLC
Louisville, KY 40299 (US)

(72) Inventors:
  • BRENNAN, Mark, David
    Jeffersonville, Indiana 47130 (US)
  • RAMSEY, Timothy, Lynn
    Shelbyville, KY 40065 (US)

(74) Representative: Coehn, Markus 
Fish & Richardson P.C. Mies-van-der-Rohe-Strasse 8
80807 München
80807 München (DE)


(56) References cited: : 
WO-A1-2008/055341
US-A1- 2008 206 768
   
  • LEUCHT S ET AL: "What does the PANSS mean?", SCHIZOPHRENIA RESEARCH, ELSEVIER, NETHERLANDS, vol. 79, no. 2-3, 15 November 2005 (2005-11-15), pages 231-238, XP027835369, ISSN: 0920-9964 [retrieved on 2005-11-15]
  • RILEY BRIEN ET AL: "Molecular genetic studies of schizophrenia", EUROPEAN JOURNAL OF HUMAN GENETICS, KARGER, BASEL, CH, vol. 14, no. 6, 1 June 2006 (2006-06-01), pages 669-680, XP002519427, ISSN: 1018-4813, DOI: 10.1038/SJ.EJHG.5201571
  • BERTOLINO ET AL: "COMT Val<158>Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia", SCHIZOPHRENIA RESEARCH, ELSEVIER, NETHERLANDS, vol. 95, no. 1-3, 29 August 2007 (2007-08-29), pages 253-255, XP022217143, ISSN: 0920-9964, DOI: 10.1016/J.SCHRES.2007.06.014
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).